7.7.3. further-line systemic therapy metastatic disease. 7.7.3.1. introduction due results ev-302/keynote a39 trial expected paradigm shift first-line therapy establishment ev plus pembrolizumab combination, well checkmate 901 trial combination cisplatin, gemcitabine nivolumab, selecting subsequent therapy lines patients fail progress first-line treatment poses significant challenge. depending choice first-line therapy following options exist. 7.7.3.2. chemotherapy patients eligible combination therapy received ev plus pembrolizumab, platinum-based chemotherapy gemcitabine plus cisplatin carboplatin may considered, however, data limited new post ev plus pembrolizumab clinical disease state toxicities, e.g. neuropathy prior therapy must taken consideration determining treatment plan. patients already received platinum-based chemotherapy without immunotherapy -line chemotherapy data highly variable mainly derive small single-arm phase ii trials apart one single phase iii rct. reasonable strategy re-challenge former platinum-sensitive patients progression occurred least six twelve months first-line platinum-based combination chemotherapy. retrospective analysis 296 patients within risc cohort (retrospective international study cancers urothelium) revealed subsequent platinum-based combination chemotherapy achieved somewhat higher disease control rate (57.4% vs. 44.8%, p.= 0.041) os (7.9 vs. 5.5 months, p = 0.035) compared subsequent non-platinum-based chemotherapy . second-line response rates single-agent treatment paclitaxel (weekly), docetaxel, gemcitabine, nab-paclitaxel, oxaliplatin, ifosfamide, topotecan, pemetrexed, lapatinib, gefitinib bortezomib ranged 0% 28% small phase ii trials . paclitaxel/gemcitabine combination shown good response rates small single-arm studies adequate phase iii rct conducted . vinflunine tested phase iii rct compared bsc patients progressing first-line treatment platinum-based chemotherapy . results showed modest orr (8.6%), clinical benefit favourable safety profile survival benefit, however statistically significant eligible patient population (not itt population). randomised phase iii trial evaluated addition angiogenesis inhibitor ramucirumab docetaxel chemotherapy vs. docetaxel alone, resulted improved pfs (4.1 vs. 2.8 months) higher response rates (24.5% vs. 14%) os benefit achieved . 7.7.3.3. immunotherapy platinum-pre-treated patients without previous immunotherapy immune checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab demonstrated similar efficacy safety patients progressing during, after, previous platinum-based chemotherapy phase i, ii iii trials. pembrolizumab demonstrated significant os improvement second-line treatment phase iii rct leading ema fda approval. patients (n = 542) randomised receive either pembrolizumab monotherapy chemotherapy (paclitaxel, docetaxel vinflunine). median os pembrolizumab 10.3 months (95% ci: 8.0–11.8) vs. 7.4 months (95% ci: 6.1–8.3) chemotherapy (hr 0.73, 95% ci: 0.59–0.91, p = 0.002) independent pd-l1 expression levels . atezolizumab first checkpoint inhibitor approved fda metastatic uc based results phase ii trials , however, indication subsequently withdrawn. phase iii rct (imvigor211) included 931 patients comparing atezolizumab second-line chemotherapy (paclitaxel, docetaxel vinflunine) meet primary endpoint improved os patients high pd-l1 expression 11.1 months (atezolizumab) vs. 10.6 (chemotherapy) months (stratified hr: 0.87, 95% ci: 0.63–1.21, p = 0.41) . pd-1 inhibitor nivolumab approved fda based results single-arm phase ii trial (checkmate 275), enrolling 270 platinum pre-treated patients. primary endpoint orr 19.6%, os 8.74 months entire group . titan-tcc study evaluated safety activity nivolumab induction plus high-dose ipilumumab (3 mg/kg) boosts non-responders (stable progressive disease) second-line treatment 83 patients metatsatic uc. fifty (60%) received least one boost investigator-assessed response rate 33% (cr: 7%), demonstrating promising outcomes strategy compared rate reported checkmate 275 . 7.7.3.4. side-effect profile immunotherapy checkpoint inhibitors including pd-1 pd-l1 antibodies ctla-4 antibodies distinct side-effect profile associated mechanism action leading enhanced immune system activity. aes affect organ body leading mild, moderate severe side effects. common organs affected skin, gi tract, liver, lung, thyroid, adrenal pituitary gland. systems may affected include musculoskeletal, renal, nervous, haematologic, ocular cardiovascular system. change immunotherapy treatment raise suspicion possible relation treatment. nature immune-related aes well characterised published . timely appropriate treatment immune-related side effects crucial achieve optimal benefit treatment maintaining safety. clear guidelines side-effect management published . immunotherapy treatment applied supervised trained clinicians ensure early side effect recognition treatment. case interruption immunotherapy, re-challenge require close monitoring aes .